Lundbeck's hopes have high costs: "You won't see us reaching that level in the future"
Pharmaceutical company Lundbeck has upgraded its R&D expenses due to high stakes on migraine drug Vyepti. The level is unnaturally high but will fluctuate in the future, says head of R&D.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
In the last year, Denmark's second-largest pharmaceutical company, Lundbeck, has upgraded its expenses for research and development, not least due to its major stakes on turning migraine drug Vyepti into a blockbuster.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck CEO's pay cut in half in 2020
For subscribers
